---
title: "HUATU CENDES plans to distribute a profit of 2 yuan per 10 shares for the first three quarters of 2024"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/223083550.md"
description: "According to the Zhitong Finance APP, HUATU CENDES disclosed the profit distribution plan for the first three quarters of 2024. The company intends to distribute a cash dividend of 2 yuan (tax included) for every 10 shares to all shareholders. This time, no bonus shares will be issued, and there will be no capital reserve fund conversion to increase share capital"
datetime: "2024-12-23T10:44:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/223083550.md)
  - [en](https://longbridge.com/en/news/223083550.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/223083550.md)
generator: "portal-rs"
---

# HUATU CENDES plans to distribute a profit of 2 yuan per 10 shares for the first three quarters of 2024

According to the Zhitong Finance APP, HUATU CENDES (300492.SZ) disclosed its profit distribution plan for the first three quarters of 2024. The company intends to distribute a cash dividend of 2 yuan (tax included) for every 10 shares to all shareholders. This time, no bonus shares will be issued, and there will be no capital reserve fund conversion to increase share capital

### Related Stocks

- [300492.CN](https://longbridge.com/en/quote/300492.CN.md)

## Related News & Research

- [11:12 ETNarxoz Business School obtiene la prestigiosa acreditación conjunta de AMBA y BGA](https://longbridge.com/en/news/297934091.md)
- [Align Capital’s Marco Sealing Solutions acquires Global O-Ring and Seal](https://longbridge.com/en/news/297905587.md)
- [ZAWYA: Subsea7 awarded contract by LLOG for US Gulf development](https://longbridge.com/en/news/297898955.md)
- [Xinhua Pharma unit Xincat’s azithromycin tablets pass China generic consistency evaluation](https://longbridge.com/en/news/297485179.md)
- [Citrix completes acquisition of Numecent](https://longbridge.com/en/news/297656377.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**